Product Code: 978-1-68038-786-5
High Resolution Melting Analysis Market Growth & Trends:
The global high resolution melting analysis market size is expected to reach USD 385.6 billion by 2030, growing at a CAGR of 3.32% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics.
Based on analyzing the disease trends and relatively lower treatment rates suggests that the demand for gene mutation and other genomic tests are expected to increase significantly over the next few years. Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach. The U.S. FDA has already approved some of the treatments which are designed to meet the requirements of a specific genetic makeup or the genomic profile of the patient's tumor.
For instance, the U.S FDA has approved a new treatment for cystic fibrosis (CF) in January, 2012. The drug kalydeco was approved for patients reported to have a specific genetic mutation known as "G551D mutation. The number of mutations which can lead to CF is in hundreds, and the G551D mutation is responsible for nearly 4% of the cases in the U.S.
Furthermore, in 2015, the Obama administration has announced the Precision Medicine Initiative with an investment of USD 216 million in the 2016 president's budget. This initiative is expected to positively reinforce the HRM analysis market over the forecast period.
High Resolution Melting Analysis Market Report Highlights:
- Clinical diagnostics is anticipated to be the fastest-growing segment, with a CAGR of 4.6% through 2030
- The detection of acquired mutations/mutation scanning/SNP typing segment held a significant revenue share in 2022 and the segment is also expected to advance at a significant CAGR over the forecast period.
- In 2022, North America dominated the overall HRM analysis market with a share of nearly 45%. Key factors attributed are high disease prevalence rates, presence of large number of academic universities; strong pharmaceutical and biotech industry, presence of large number genetic testing centers, and rapid adoption of novel technologies for improving the healthcare outcomes.
- Asia pacific is identified as the fastest growing region over the forecast period. Key reasons attributed are increasing public and private expenditure on molecular diagnostics and genetic testing, increasing prevalence of genetic disorders, and increasing burden of chronic diseases such as cancer, COPD, HIV and others.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product
- 1.1.2. Application
- 1.1.3. End use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Application
- 2.2.3. End use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. High Resolution Melting Analysis Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. High Resolution Melting Analysis Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's Five Forces
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. High Resolution Melting Analysis Market: Product Estimates & Trend Analysis
- 4.1. High Resolution Melting Analysis Market: Key Takeaways
- 4.2. High Resolution Melting Analysis Market: Product Movement & Market Share Analysis, 2022 & 2030
- 4.3. Instruments
- 4.3.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Reagents
- 4.4.1. Reagents market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Software
- 4.5.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. High Resolution Melting Analysis Market: Application Estimates & Trend Analysis
- 5.1. High Resolution Melting Analysis Market: Key Takeaways
- 5.2. High Resolution Melting Analysis Market: Application Movement & Market Share Analysis, 2022 & 2030
- 5.3. Detection of Acquired Mutations/Mutation Scanning/SNP Typing
- 5.3.1. Detection of acquired mutations/mutation scanning/SNP typing market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Microbial Species Identification
- 5.4.1. Microbial species identification market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Zygosity testing
- 5.5.1. Zygosity testing market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Epigenetics/Methylation Profiling and Drug-Resistant
- 5.6.1. Epigenetics/methylation profiling and drug-resistant market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. High Resolution Melting Analysis Market: End-use Estimates & Trend Analysis
- 6.1. High Resolution Melting Analysis Market: Key Takeaways
- 6.2. High Resolution Melting Analysis Market: End-use Movement & Market Share Analysis, 2022 & 2030
- 6.3. Academic Research
- 6.3.1. Academic research market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Clinical Diagnostics
- 6.4.1. Clinical diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. High Resolution Melting Analysis Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. High Resolution Melting Analysis Market by Region: Key Takeaways
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Denmark
- 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Norway
- 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
- 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.2.1. Thermo Fisher Scientific Inc.
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Bio-Rad Laboratories, Inc.
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. F. Hoffman-La Roche Ltd.
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Bio Farma
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. QIAGEN
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Illumina, Inc.
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Agilent Technologies, Inc.
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. BIOMERIEUX
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Meridian Bioscience, Inc.
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Novacyt
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives
- 8.2.11. PREMIER Biosoft
- 8.2.11.1. Company overview
- 8.2.11.2. Financial performance
- 8.2.11.3. Product benchmarking
- 8.2.11.4. Strategic initiatives
- 8.2.12. Azura Genomics Inc.
- 8.2.12.1. Company overview
- 8.2.12.2. Financial performance
- 8.2.12.3. Product benchmarking
- 8.2.12.4. Strategic initiatives
- 8.2.13. CANON MEDICAL SYSTEMS CORPORATION
- 8.2.13.1. Company overview
- 8.2.13.2. Financial performance
- 8.2.13.3. Product benchmarking
- 8.2.13.4. Strategic initiatives